How to Fight Insurance Denials for Inflammatory Bowel Disease Treatment

Inflammatory bowel disease—Crohn's disease and ulcerative colitis—often requires powerful medications to control inflammation, prevent bowel damage, and avoid surgery. Yet insurers routinely deny coverage for biologics (anti-TNF agents, IL-12/23 and IL-23 inhibitors, integrin blockers), JAK inhibitors, S1P modulators, therapeutic drug monitoring, and even indicated surgeries. Denials are common because these therapies are expensive, because prior authorization policies impose rigid step-therapy rules that don't match clinical reality, and because medical directors apply outdated cost-containment protocols to a field where the evidence base evolves rapidly. This guide explains the most common denial templates, the specific clinical evidence and policy citations insurers actually respect, and concrete steps to overturn each type of denial.

---

Why Insurers Deny IBD Treatment

1. Step therapy not completed

The insurer requires you to fail 5-ASA, corticosteroids, thiopurines, or an older biologic (usually an anti-TNF like Humira or Remicade) before approving a newer agent—Stelara, Skyrizi, Tremfya, Entyvio, Rinvoq, Zeposia, or Velsipity. The policy may demand sequential trials of multiple anti-TNFs even when you've already developed anti-drug antibodies to the first one.

2. "Not medically necessary" for your disease severity

The denial letter states that your disease is not severe enough to warrant a biologic or advanced therapy. This is common when you have endoscopic inflammation but low symptom scores, or when biomarkers (CRP, fecal calprotectin) are elevated but you're not hospitalized. Insurers may cite the lack of "acute severe" criteria even when you have moderate-to-severe disease by validated indices.

3. Therapeutic drug monitoring (TDM) not covered

The plan refuses to pay for serum drug levels and anti-drug antibody testing for infliximab, adalimumab, vedolizumab, or ustekinumab, calling it "experimental" or "not standard of care," despite published guidelines endorsing proactive and reactive TDM.

4. Drug not FDA-approved for your IBD subtype

You have Crohn's disease and the insurer denies Simponi, Xeljanz, Zeposia, or Velsipity (UC-only indications), or you have ulcerative colitis and the insurer denies Cimzia (CD-only). The denial cites the FDA label even when off-label use is evidence-based and guideline-supported.

5. Surgery denial or requirement to "try more drugs first"

The insurer denies coverage for ileocecal resection, strictureplasty, or colectomy, arguing that you haven't exhausted all medical options—even when you have refractory disease, fibrotic strictures, dysplasia, or would benefit from the bowel-sparing approach demonstrated in trials like LIR!C.

---

The Citations Insurers Respect

When appealing, reference these specific guidelines, trials, and policy statements by name and year. Generic statements like "studies show" carry no weight; payers respond to named evidence.

Guidelines and consensus statements

• AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During Pregnancy (2021) — addresses biologic safety and continuation during pregnancy.
• AGA Clinical Practice Guidelines on the Role of Biomarkers for the Management of IBD (2023) — endorses fecal calprotectin and CRP for disease monitoring.
• AGA Clinical Practice Update on Therapeutic Drug Monitoring in IBD (2017) — specifies trough thresholds (infliximab ≥5 µg/mL, adalimumab ≥7.5 µg/mL, vedolizumab ≥20 µg/mL, ustekinumab ≥4.5 µg/mL) and recommends dose optimization or class switch based on drug levels and anti-drug antibodies.
• ACG Clinical Guideline: Ulcerative Colitis in Adults (2019) — outlines induction and maintenance strategies, step-therapy rationale, and treat-to-target endpoints.
• ACG Clinical Guideline: Management of Crohn's Disease in Adults (2018) — details phenotype-based treatment, anti-TNF use in fistulizing and stricturing disease, and post-operative prophylaxis.
• ECCO/ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects (2019) — validates Mayo, partial Mayo, CDAI, HBI, SES-CD, and Rutgeerts scores.

Pivotal trials (by drug, with year and journal when available)

• Remicade (infliximab): ACCENT-1 (Crohn's maintenance, 2002), ACCENT-2 (fistulizing Crohn's, 2004), ACT-1 and ACT-2 (UC, NEJM 2005)
• Humira (adalimumab): CLASSIC-I (Crohn's induction, Gastroenterology 2006), ULTRA-1 and ULTRA-2 (UC, Gastroenterology 2012)
• Cimzia (certolizumab pegol): PRECISE-1 and PRECISE-2 (Crohn's, Gastroenterology 2007)
• Simponi (golimumab): PURSUIT-SC induction and PURSUIT-Maintenance (UC, Gastroenterology 2014)
• Stelara (ustekinumab): UNITI-1, UNITI-2, IM-UNITI (Crohn's, NEJM 2016), UNIFI (UC, Lancet 2019)
• Skyrizi (risankizumab): ADVANCE, MOTIVATE, FORTIFY (Crohn's, NEJM 2022), INSPIRE and COMMAND (UC, NEJM 2024)
• Tremfya (guselkumab): QUASAR induction and maintenance (UC, NEJM 2024); GALAXI program ongoing for Crohn's
• Entyvio (vedolizumab): GEMINI-1 (UC), GEMINI-2 and GEMINI-3 (Crohn's, NEJM 2013); VARSITY head-to-head vs adalimumab in UC (Lancet Gastro Hep 2019)
• Xeljanz (tofacitinib): OCTAVE Induction 1 and 2, OCTAVE Sustain (UC, NEJM 2017)
• Rinvoq (upadacitinib): U-ACHIEVE, U-ACCOMPLISH (UC induction, Lancet 2022), U-EXCEED, U-EXCEL (Crohn's, NEJM 2023)
• Zeposia (ozanimod): True North induction and maintenance (UC, NEJM 2021)
• Velsipity (etrasimod): ELEVATE-UC-12 and ELEVATE-UC-52 (UC, Lancet 2023)
• LIR!C trial (Lancet Gastro Hep 2020): demonstrated that early ileocecal resection is non-inferior to anti-TNF therapy for limited ileocolonic Crohn's, supporting surgery as a valid first-line option rather than last resort.

Key concepts to invoke

• Treat-to-target (STRIDE-II, 2021): The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II) consensus defines treatment goals as clinical remission plus endoscopic healing (Mayo Endoscopic Subscore ≤1 for UC, SES-CD ≤2 or absence of ulceration for Crohn's), with normalization of biomarkers. Cite this when the insurer claims your treatment is unnecessary because you're "not symptomatic enough"—endoscopic inflammation predicts relapse, hospitalization, and surgery even when symptoms are controlled.
• Pharmacokinetic vs pharmacodynamic failure (AGA TDM 2017): When a biologic stops working, TDM distinguishes low drug levels (pharmacokinetic failure → dose escalate or shorten interval) from adequate levels with loss of response (pharmacodynamic/mechanistic failure → switch class or mechanism). This justifies switching from anti-TNF to IL-23 inhibitor, integrin blocker, or JAK inhibitor rather than cycling through more anti-TNFs.
• Anti-drug antibodies (immunogenicity): High-titer anti-drug antibodies (especially to infliximab or adalimumab) predict treatment failure and are not reliably overcome by dose escalation. Document positive ADA titers and cite AGA TDM 2017 to justify immediate class switch.
• Montreal classification (Crohn's) and extent (UC): Phenotype determines appropriate therapy. Perianal fistulizing Crohn's (B3p) responds preferentially to anti-TNF agents (ACCENT-2 trial). Extensive UC (E3, pancolitis) or left-sided UC with high Mayo Endoscopic Subscore warrants advanced therapy even without hospitalization.

---

How to Argue Against Step-Therapy Denials

The insurer says: "You must fail [5-ASA / thiopurines / Humira / another anti-TNF] before we cover [Stelara / Skyrizi / Entyvio / Rinvoq / etc.]."

Concrete steps

1. Obtain a detailed letter of medical necessity from your gastroenterologist. The letter must document:

- Your IBD phenotype (Crohn's location and behavior per Montreal classification; UC extent per Montreal E1-E3).

- Disease activity scores: Mayo or partial Mayo (UC), CDAI or HBI (Crohn's), endoscopic scores (Mayo Endoscopic Subscore for UC, SES-CD or Rutgeerts for Crohn's), and objective biomarkers (CRP, fecal calprotectin).

- Every prior IBD therapy, dose, duration, and outcome—including why you cannot retry or continue each agent (primary non-response, secondary loss of response, intolerance, contraindication).

- TDM results if available, with interpretation per AGA TDM 2017 thresholds.

- Why the requested drug's mechanism of action is appropriate for your disease (e.g., gut-selective integrin inhibitor for anti-TNF-experienced patient; IL-23 inhibitor for anti-TNF antibody-mediated failure; JAK inhibitor for rapid severe UC).

2. Cite specific contraindications or documented failure. For example:

- Thiopurine intolerance: "Patient experienced acute pancreatitis on azathioprine (a known idiosyncratic reaction occurring in 3-7% of IBD patients, per ACG 2018 Crohn's guideline), precluding rechallenge."

- Anti-TNF antibody-mediated failure: "Infliximab trough 1.2 µg/mL with anti-infliximab antibodies 4.8 U/mL (positive) on Prometheus assay. Despite dose escalation to 10 mg/kg q6wk, trough remained subtherapeutic at 2.1 µg/mL with persistent high-titer antibodies. Per AGA TDM 2017, high-titer ADA predicts treatment futility; switching to a different mechanism (IL-23 inhibitor or integrin blocker) is indicated rather than another anti-TNF."

- Primary non-response with adequate drug levels: "Adalimumab induction and maintenance at standard dosing for 14 weeks. Trough level 8.2 µg/mL (above AGA threshold of 7.5 µg/mL), no anti-drug antibodies detected, yet partial Mayo score unchanged and fecal calprotectin remained >1000 µg/g. This represents mechanistic (pharmacodynamic) failure, not pharmacokinetic underdosing, and justifies switch to alternate mechanism per AGA TDM 2017."

3. Invoke STRIDE-II treat-to-target. Explain that symptom control alone is insufficient; achieving endoscopic remission and biomarker normalization reduces hospitalization, surgery, and disability. If you've trialed one or two agents without reaching these targets, prolonged step therapy delays appropriate treatment and increases risk of irreversible bowel damage.

4. Request an expedited peer-to-peer review. Your gastroenterologist calls the plan's medical director and walks through your case, emphasizing the evidence above. Many denials are overturned when a specialist explains that rigid step therapy does not apply to your clinical scenario.

5. File a formal appeal citing the specific guideline and trial evidence. Include:

- ACG or AGA guideline sections stating that patients who fail or are intolerant to one class may proceed directly to an alternative mechanism.

- Head-to-head data (e.g., VARSITY trial showing vedolizumab superior to adalimumab in UC) if relevant.

- Your state's step-therapy override law if applicable (many states require insurers to grant exceptions for contraindication, likely ineffectiveness based on prior therapy, or patient harm from delay).

---

How to Argue Against "Not Medically Necessary" Denials

The insurer says: "Your disease is not severe enough" or "Biologic therapy is not indicated for mild disease."

Concrete steps

1. Document objective disease severity. Include in your appeal:

- Endoscopy report with photos: Mayo Endoscopic Subscore (UC) or SES-CD/ulcer presence (Crohn's). Even if you have few symptoms, an MES of 2-3 or deep Crohn's ulcers demonstrate moderate-to-severe endoscopic disease, which predicts poor outcomes without advanced therapy.

- Biomarkers: Fecal calprotectin >250 µg/g and/or elevated CRP indicate active inflammation. Cite AGA 2023 biomarker guideline stating these objectively confirm disease activity and need for treatment escalation.

- Validated activity indices: Partial Mayo ≥5 (UC) or HBI >4 / CDAI >220 (Crohn's) define moderate disease. Cite ECCO/ESGAR 2019 guideline endorsing these scores.

2. Cite STRIDE-II target remission criteria. The 2021 STRIDE-II consensus—endorsed by major GI societies—states that treatment targets are symptomatic remission and endoscopic healing, not symptoms alone. Explain that your elevated Mayo Endoscopic Subscore or SES-CD means you have not achieved target remission, and that failure to treat endoscopic inflammation leads to complications (hospitalization, surgery, permanent bowel damage). This shifts the burden: the insurer must justify not treating objective inflammation, not you justify treating "mild symptoms."

3. Emphasize extraintestinal manifestations or complications. If you have:

- Perianal fistulas (cite ACCENT-2 trial for anti-TNF efficacy).

- Stricturing or penetrating Crohn's (B2/B3 phenotype) requiring bowel-sparing medical therapy to avoid or delay surgery.

- Extraintestinal manifestations (arthritis, pyoderma gangrenosum, erythema nodosum, uveitis, primary sclerosing cholangitis)—these often respond to systemic biologic therapy even when bowel symptoms are mild.

- Steroid dependence (unable to taper below 10-20 mg prednisone without flare)—this alone is an indication for steroid-sparing biologic or immunomodulator per ACG guidelines.

4. Provide evidence of disease progression. Compare prior endoscopy or imaging to current findings. Document worsening extent (e.g., proctitis → left-sided → pancolitis), new complications (stricture, fistula), rising biomarkers, or increased symptom frequency. Argue that delaying treatment risks progression to surgery or irreversible fibrosis.

5. Cite the specific FDA indication and pivotal trial. If the insurer claims the drug is not indicated, quote the FDA approval and trial endpoints. For example: "Skyrizi received FDA approval for moderately to severely active Crohn's disease in June 2022 based on ADVANCE, MOTIVATE, and FORTIFY trials (NEJM 2022), which enrolled patients with CDAI 220-450 and endoscopic ulceration—criteria my patient meets."

---

How to Argue Against TDM Denials

The insurer says: "Therapeutic drug monitoring is experimental / investigational / not covered."

Concrete steps

1. Cite the AGA Clinical Practice Update on TDM in IBD (2017). This widely adopted guideline endorses both reactive TDM (checking levels when a patient loses response) and proactive TDM (periodic monitoring even in remission). Quote: "Therapeutic drug monitoring is recommended to guide dose optimization and distinguish pharmacokinetic failure from pharmacodynamic failure in patients on anti-TNF, vedolizumab, or ustekinumab therapy."

2. Explain the clinical utility. TDM results determine whether to:

- Increase dose or shorten interval (if drug level is low and no antibodies).

- Switch to another drug in the same class with different immunogenicity profile (if low level plus antibodies, e.g., infliximab → adalimumab).

- Switch to a different mechanism (if adequate level but clinical loss of response → mechanistic failure).

- Without TDM, these decisions are guesswork, risking ineffective dose escalation, unnecessary medication trials, and worse outcomes.

3. Document the specific clinical question. Your appeal should state: "Patient on infliximab 5 mg/kg q8wk experienced loss of response at week 30 after initial remission. TDM is medically necessary to determine whether this represents low drug levels (requiring dose escalation), anti-drug antibodies (requiring class switch), or adequate levels with mechanistic failure (requiring switch to IL-23 inhibitor, integrin blocker, or JAK inhibitor). AGA TDM 2017 explicitly recommends this testing in this scenario."

4. Compare cost of TDM to cost of empiric treatment change. A TDM panel costs $200-500; an unnecessary biologic switch or prolonged trial of ineffective dose escalation costs tens of thousands. Argue that TDM is cost-effective and standard of care.

5. Appeal under your plan's laboratory benefits or prior authorization for lab testing. Some plans deny TDM under pharmacy benefit but cover it under lab benefit if ordered with correct CPT codes (e.g., 80230 for infliximab level, 86200 or 83520 for antibodies). Work with your GI and lab to ensure correct coding and medical necessity documentation.

---

How to Argue Against FDA-Label ("Off-Label") Denials

The insurer says: "This drug is not FDA-approved for your type of IBD" (e.g., denying Xeljanz for Crohn's, or Cimzia for UC).

Concrete steps

1. Cite your state insurance law and plan documents on off-label use. Most state laws and plan policies allow off-label use if it is supported by:

- Peer-reviewed medical literature.

- Compendia (e.g., AHFS Drug Information, Micromedex, NCCN for cancer).

- Standard-of-care or guideline-supported use.

2. Provide evidence for off-label use. For example:

- Cimzia for UC: Although only FDA-approved for Crohn's, certolizumab is an anti-TNF with the same mechanism as infliximab and adalimumab (both approved for UC). Cite ACG 2019 UC guideline or literature showing anti-TNF class effect in UC.

- JAK inhibitors for Crohn's (if Rinvoq not yet tried): Tofacitinib has been studied in Crohn's (NEJM 2017 phase 2 trial showed efficacy); JAK inhibition is a validated mechanism. If patient has failed anti-TNF and IL-12/23 or IL-23 inhibitors, off-label use is reasonable.

3. Explain why FDA-approved alternatives are not appropriate. If the insurer insists on an on-label drug, detail why you cannot use it (e.g., already failed, contraindicated, not available in your formulation or route of administration).

4. Request an exception or formulary override. Many plans have a formal process for off-label drug exceptions. Your physician submits a letter citing the evidence above, and the plan's P&T committee reviews it.

---

How to Argue Against Surgery Denials

The insurer says: "You must try additional medications before surgery" or "Surgery is not medically necessary."

Concrete steps

1. Document the indication for surgery. Include:

- Refractory disease despite biologic therapy: "Patient has failed infliximab, adalimumab, ustekinumab, and vedolizumab with documented loss of response and TDM-guided optimization. Persistent active disease with Mayo Endoscopic Subscore 3, requiring ongoing corticosteroids. ACG 2019 UC guideline lists medically refractory disease as an indication for colectomy."

- Dysplasia or cancer risk: "Colonoscopy shows low-grade dysplasia in the setting of long-standing pancolitis (>10 years). Per ACG and AGA surveillance guidelines, colectomy is indicated to prevent colorectal cancer."

- Fibrostenotic stricture (Crohn's): "Imaging shows fibrotic ileal stricture causing obstructive symptoms. Strictureplasty or resection is indicated; anti-inflammatory therapy will not reverse fibrosis. ACG 2018 Crohn's guideline endorses surgery for symptomatic fibrostenotic disease."

- Perianal fistula not responding to medical therapy: "Complex perianal fistulas with persistent drainage despite seton placement, metronidazole/ciprofloxacin, and infliximab therapy. Surgical management (fistulotomy, advancement flap, or fecal diversion) is necessary per ASCRS guidelines."

- LIR!C trial data (for ileocecal resection): "Patient has limited ileocolonic Crohn's. LIR!C trial (Lancet Gastro Hep 2020) demonstrated that early ileocecal resection is non-inferior to anti-TNF therapy for this phenotype, with lower complication rates and similar long-term outcomes. Surgery is a valid first-line option, not a last resort."

2. Obtain a letter from your surgeon and GI. The letter should state the specific procedure planned, the indication, and why further medical therapy is unlikely to avoid surgery or will cause harm (e.g., prolonged steroid exposure, malnutrition, risk of perforation).

3. Cite guidelines explicitly endorsing surgery. ACG 2018 Crohn's guideline and ACG 2019 UC guideline both outline surgical indications. ECCO consensus statements also detail when surgery is first-line or necessary.

4. Appeal under medical necessity criteria. Surgery for medically refractory IBD, dysplasia, obstruction, or perforation is standard of care and cannot be denied as "experimental" or "cosmetic." If the plan denies on the basis that you haven't tried "all options," argue that there is no obligation to trial every agent sequentially when surgery is indicated and effective.

5. Request peer-to-peer review with your surgeon. A colorectal surgeon can explain the surgical rationale and outcomes data directly to the plan's medical director, often resolving denials.

---

What We Do

We help patients and physicians compile the evidence, write appeals, and prepare for peer-to-peer reviews. We organize your medical records, TDM results, endoscopy reports, and biomarkers; draft letters citing the specific guidelines and trials payers actually respect; and coordinate with your care team to make the case clearly and quickly. If you've been denied coverage for a biologic, JAK inhibitor, TDM, or IBD surgery, we can help you fight back with the documentation and arguments that work.

---

Sources

1. American Gastroenterological Association. Clinical Practice Update on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology 2017.

2. American Gastroenterological Association. Clinical Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020; and ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol 2019.

3. American College of Gastroenterology. Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2018.

4. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II): Update from the International Organization for the Study of Inflammatory Bowel Diseases. Gastroenterology 2021.

5. Bemelman WA, et al. (LIR!C trial). Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol 2020.

6. Feagan BG, et al. (GEMINI). Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2013.

7. Sands BE, et al. (UNITI, IM-UNITI). Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med 2016.

8. Sands BE, et al. (UNIFI). Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Lancet 2019.

9. Feagan BG, et al. (ADVANCE, MOTIVATE, FORTIFY). Risankizumab for Moderately to Severely Active Crohn's Disease. N Engl J Med 2022.

10. D'Haens G, et al. (INSPIRE, COMMAND). Risankizumab for Moderately to Severely Active Ulcerative Colitis. N Engl J Med 2024.

11. Danese S, et al. (QUASAR). Guselkumab for Ulcerative Colitis. N Engl J Med 2024.

12. Sandborn WJ, et al. (OCTAVE). Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2017.

13. Loftus EV Jr, et al. (U-ACHIEVE, U-ACCOMPLISH). Upadacitinib Induction and Maintenance Therapy for Ulcerative Colitis. Lancet 2022; and for Crohn's Disease. N Engl J Med 2023.

14. Sandborn WJ, et al. (True North). Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2021.

15. Vermeire S, et al. (ELEVATE). Etrasimod for Ulcerative Colitis. Lancet 2023.

16. American Gastroenterological Association. Clinical Practice Guidelines on the Role of Biomarkers for the Management of IBD. Gastroenterology 2023.

17. Maaser C, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019.